OM · Outset Medical, Inc.
$4.72
+0.40 (+9.26%)
At close · Jul 28
Market Cap
$87.50M
Shares
18.54M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.72
Open$4.32
Day$4.32–4.84
52W$3.00–18.63
Avg vol 30d265K
Short int1.2M · 6.6% float · 6.3d
Short vol40%
Last earningsJun 17, 2026
DataSep 2020–Jul 2026
Filing10-Q · May 7
Up next
Next earnings call
Sep 20, 2026
Est · unconfirmed
· in 8 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Neutral
Sentiment
Bullish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−12%
below
Price vs 50-day avg
+6%
above
RSI (14)
56
neutral
MACD trend
Positive
52-week position
11%
near low
Volume (OBV)
Bearish div.
distributing
Momentum
relative strength
1-month return
+3%
trailing
6-month return
−5%
trailing
YTD return
+27%
this year
Relative strength
−12%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $5 — 200d above 50d
Institutional flow
Accumulating
18 of 97 funds reported for Jun 30 · net +226.3K sh shares · +5 new
Insider flow
Distributing
Net -$115.7K over 90 days · 100% sells
Short interest
Falling
6.56% of float · ▼ -18.5% MoM · 6.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
97 holders — near 1-yr high, broad support
Squeeze score
62
elevated · 0–100
Fundamentals
Revenue growth
+5%
Y/Y
Gross margin
39%
expanding
EPS growth
+85%
Y/Y
Free cash flow
$-47.1M
Balance sheet
$66.0M
net debt
Quant / Vol
risk profile
Volatility
101%
annualized · 1-yr
Max drawdown
−83%
past year
ATR
8.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 7, 2026
Revenue
· 2026
Initiated
$125M – $130M
prior FY $119.48M
midpoint +6.7% Y/Y
Guided vs delivered
· last 1 settled
Revenue
full year 2024
guided $112M
$113.69M
Beat +1.5%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−12%
Bearish
Price vs 50-day avg
+6%
Bullish
RSI (14)
56
Neutral
MACD trend
Positive
Bullish
52-week position
11%
Bearish
Volume (OBV)
Bearish div.
Bearish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $4 › 200d $5 — 200d above 50d
Institutional flow
Accumulating
18 of 97 funds reported for Jun 30 · net +226.3K sh shares · +5 new
Insider flow
Distributing
Net -$115.7K over 90 days · 100% sells
Short interest
Falling
6.56% of float · ▼ -18.5% MoM · 6.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
97 holders — near 1-yr high, broad support
Price context
position in its 52-week range
52-wk low $3
Now $5 · 11%
52-wk high $19
vs 200-day avg -12%
vs 50-day avg +6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Net cash used during the quarter | $12M | first quarter ended March 31, 2026 | — |
| Gross margin | 39.1% | FY2025 | — |
| Net cash used in operations | $46M | FY2025 | — |
| Non-GAAP gross margin non-GAAP | 39.6% | FY2025 | — |
| Non-GAAP net loss non-GAAP | $15.1M | Q4 2025 | — |
| Non-GAAP net loss per share, diluted non-GAAP | $0.84 | Q4 2025 | — |
| Non-GAAP operating expenses non-GAAP | $25.7M | Q4 2025 | — |
| Recurring revenue | $88.7M | FY2025 | — |
| Recurring revenue consisting of Tablo consumables and services | $22.5M | Q4 2025 | — |
| Total cash, including restricted cash, cash equivalents and investment securities | $172.8M | FY2025 | — |
| Year-end cash, including restricted cash, cash equivalents and short-term investments | $173M | Q4 2025 | — |
| Cumulative treatments on Tablo | 3M | Exiting 2025 | — |
| Sites of care that have insourced dialysis with Outset | 1,000 | Exiting 2025 | — |
| Treatments performed per year | 1M | Exiting 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
OM
this stock
Outset Medical, Inc.
|
$87.50M | +27.2% | +5.1% | — | 6.6% |
|
ABT
Abbott Laboratories
|
$186.84B | -13.9% | +5.7% | 30.1 | 1.4% |
|
SYK
Stryker Corp
|
$132.87B | -1.1% | +11.2% | 40.1 | 1.8% |
|
MDT
Medtronic plc
|
$111.21B | -8.8% | +8.4% | 23.3 | 1.5% |
|
BSX
Boston Scientific Corp
|
$68.46B | -51.7% | +5.5% | 19.3 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| OM | +16.3% | +3.1% | -5.0% | +9.3% | +27.2% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | +17.3% | +3.1% | -12.5% | +10.1% | +18.6% |
Key facts
CIK
1484612
CUSIP
690145206
13F (30d)
16 filings
16 filers
Visit website
Investor relations